Versant Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Versant Capital Management's VRDN Position: Q3 2026 in Review
Versant Capital Management held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 148 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.
Versant Capital Management first reported a position in VRDN in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.22K in Q1 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Versant Capital Management held 148 shares of Viridian Therapeutics worth $3.05K as of Q3 2026.
- Versant Capital Management left its Viridian Therapeutics share count unchanged in Q3 2026.
- Viridian Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2547 holding.
- Versant Capital Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Versant Capital Management's Viridian Therapeutics position peaked at $4.22K in Q1 2025.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.